At this time, a patent prevents the manufacturing of a generic version of Firmagon (degarelix). This patent is scheduled to expire in April 2017, which would be the earliest date that a generic version could become available. However, lawsuits or other patents for new uses of the drug could change this date.
Can I Buy Generic Firmagon?Firmagon® (degarelix) is a prescription medication approved to treat men with advanced prostate cancer. It works by decreasing levels of testosterone in the body, which helps to slow down the growth of prostate cancer cells.
Firmagon is manufactured by Rentschler Biotechnologie for Ferring Pharmaceuticals, Inc. It is currently under the protection of a patent that prevents any generic Firmagon from being manufactured in the United States.
When Will a Generic Version Be Available?The first patent is set to expire in April 2017. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Firmagon uses. Once the drug goes off-patent, there may be several companies that manufacture a generic Firmagon drug.
Is Degarelix a Generic Firmagon?No -- degarelix is the active ingredient in Firmagon, but it is not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine.
In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.